Buchumschlag

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituxi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hahn, Michael (VerfasserIn) , Böttcher, S. (VerfasserIn) , Dietrich, Sascha (VerfasserIn) , Hegenbart, Ute (VerfasserIn) , Rieger, Michael (VerfasserIn) , Stadtherr, Peter (VerfasserIn) , Bondong, Andrea (VerfasserIn) , Ritgen, Matthias (VerfasserIn) , Schmitt, Thomas (VerfasserIn) , Tran, Thuong Hien (VerfasserIn) , Görner, Martin (VerfasserIn) , Krämer, Isabelle (VerfasserIn) , Luft, Thomas (VerfasserIn) , Schönland, Stefan (VerfasserIn) , Witzens-Harig, Mathias (VerfasserIn) , Zenz, Thorsten (VerfasserIn) , Kneba, Michael (VerfasserIn) , Ho, Anthony Dick (VerfasserIn) , Dreger, Peter (VerfasserIn)
Weitere Verfasser: Schulz, Renate (BerichterstatterIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 6 July 2015
In: Bone marrow transplantation
Year: 2015, Jahrgang: 50, Heft: 10, Pages: 1279-1285
ISSN:1476-5365
DOI:10.1038/bmt.2015.150
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2015.150
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt2015150
Volltext
Verfasserangaben:M. Hahn, S. Böttcher, S. Dietrich, U. Hegenbart, M. Rieger, P. Stadtherr, A. Bondong, R. Schulz, M. Ritgen, T. Schmitt, T.H. Tran, M. Görner, I. Herth, T. Luft, S. Schönland, M. Witzens-Harig, T. Zenz, M. Kneba, A.D. Ho and P. Dreger
Beschreibung
Zusammenfassung:To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor lymphocyte infusions) was guided by minimal residual disease (MRD) monitoring and commenced at a median of 91 (22-273) days after alloHCT, resulting in a probability of being event free and MRD-negative 1 year after transplant of 57% (84% in those encountering chronic GvHD). Patients who were event free and MRD-negative at the 12-month landmark had a 4-year PFS of 77% and largely remained durably MRD-negative if MRD clearance had occurred subsequent to immune modulation. Three-year overall survival, PFS, relapse incidence and non-relapse mortality of all 77 patients were 69, 57, 26 and 24%, respectively. Survival was not affected by EBMT risk category but by active disease at alloHCT, which could not be overcome by intensification of conditioning. Twenty-three patients who experienced relapse post alloHCT had a survival of 56% at 2 years after CLL recurrence. In conclusion, MRD-guided immune modulation after alloHCT for high-risk CLL can provide durable MRD clearance in more than half of the patients.
Beschreibung:Gesehen am 17.03.2021
Beschreibung:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2015.150

Ähnliche Einträge